The girls of India have GOOD NEWS! Today launches the nation’s FIRST cervical cancer vaccination

The first locally manufactured quadrivalent human papillomavirus vaccination (qHPV) against cervical cancer is being introduced in the nation’s capital today, marking a significant development in Indian medical science (September 1, 2022). The Serum Institute of India (SII) received market authorization from the Drugs Controller General of India (DCGI) last month to produce a cervical cancer vaccine that was produced locally.

According to Dr. NK Arora, the Covid working group’s chair, the National Technical Advisory Group on Immunization (NTAGI) described the debut of an Indian-made vaccine as an exhilarating experience. “This much-anticipated vaccination will finally be available to our daughters and granddaughters, which is quite exciting and, I must admit, makes us very happy, said Dr. Arora. He said, “In fact, this is one of the last significant vaccines to be launched. In actuality, this is one of the final vaccines to be introduced into the program. Now that Indian vaccinations will be accessible, we anticipate their introduction into the National Immunization Program for girls aged 9 to 14 years.”

“Because this particular virus is the cause of cervical cancer in 85% to 90% of cases and this vaccine protects against those viruses, it is very effective and prevents the disease. Therefore, if we give it to our young children and daughters, they will be protected against the virus, which will likely prevent cancer from developing 30 years later “Dr. Arora went on to elaborate. “On the international market, there was a shortage. Indian vaccination has now arrived. Consequently, we will be able to meet our needs with our made-in-India vaccine “said Dr. Arora.

Union Minister of Science and Technology Jitendra Singh will launch the vaccine at IIC Delhi. SII CEO Adar Poonawalla will be present at the event, the officials said. According to the officials, the qHPV vaccine CERVAVAC has demonstrated a robust antibody response that is nearly 1,000 times higher than the baseline against all targeted HPV types and in all dose and age groups.

In India, cervical cancer is the second most common malignancy among women between the ages of 15 and 44. Prakash Kumar Singh, director of government and regulatory affairs at Serum Institute, had applied to the DCGI seeking market authorisation of qHPV after the phase second and third clinical trial was completed with the support of the Department of Biotechnology under the Ministry of Science and Technology to ensure its early availability. The DCGI’s approval had come following a recommendation by the Subject Expert Committee (SEC) on Covid-19 of the CDSCO on June 15.

Read all Latest NewsSports NewsEntertainment NewsAutomotive NewsHealth News and more here

Leave a Reply

Your email address will not be published. Required fields are marked *